Skip to content
Drix10 Blog

Songbird genetic diversity loss in China study halves in 50 years across 62 species

, 4 items in Neuroscience and AI, 3 min read

In this digest (4 items)

Songbird genetic diversity loss in China study halves in 50 years across 62 species. All 62 studied species lost nearly half their genetic diversity in roughly five decades, including common low-risk birds.

Key points

  • Species count: 62 songbird species studied in China.

  • Diversity loss: All lost nearly half their genetic diversity over roughly 50 years.

Sources

Trump executive order creates women’s health task force

Trump signed an executive order in October creating a task force on women’s health and directing NIH to set up a Women’s Health Division. The order follows prior NIH initiatives and calls for expanded congressional funding.

Key points

  • Executive order signed in October 2023 created a White House task force on women’s health.

  • NIH is directed to establish a Women’s Health Division within an existing institute.

  • Breast cancer five-year survival rose from 76% in 1975 to 94% in 2023 after sustained research investment.

  • Biden’s request for $12 billion for women’s health research was not included in the final appropriation.

Sources

SciImmunology study identifies monoclonal antibodies for new Mpox antigen targets

SciImmunology study used antibody samples from people likely vaccinated against smallpox to identify monoclonal antibodies for new Mpox antigen targets. The work aims to enable future vaccines and therapies.

Key points

  • Antibody samples from people likely vaccinated against smallpox were used.

  • Monoclonal antibodies for new Mpox antigen targets were identified.

Sources

Tozorakimab reduces COPD exacerbations in OBERON TITANIA

Tozorakimab reduced the rate of moderate or severe COPD exacerbations versus placebo in the phase 3 OBERON and TITANIA trials. Full results are linked in the research summary.

Key points

  • Two replicate phase 3 trials involving patients with COPD receiving inhaled maintenance therapy.

  • Add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo.

Sources